Drugs / ABC/DTG/3TC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03016533 | Jun 2017 → Dec 2024 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABC/DTG/3TC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03016533 ↗ |
| Known as | Abacavir/Dolutegravir/Lamivudine | “Abacavir/Dolutegravir/Lamivudine(ABC/DTG/3TC)” NCT03016533 ↗ |